CA3206455A1 - Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy - Google Patents

Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy Download PDF

Info

Publication number
CA3206455A1
CA3206455A1 CA3206455A CA3206455A CA3206455A1 CA 3206455 A1 CA3206455 A1 CA 3206455A1 CA 3206455 A CA3206455 A CA 3206455A CA 3206455 A CA3206455 A CA 3206455A CA 3206455 A1 CA3206455 A1 CA 3206455A1
Authority
CA
Canada
Prior art keywords
ldh
polypeptide
amino acid
nucleic acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3206455A
Other languages
English (en)
French (fr)
Inventor
Pierre Sonveaux
Raphael Frederick
Leopold Thabault
Maxime LIBERELLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of CA3206455A1 publication Critical patent/CA3206455A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3206455A 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy Pending CA3206455A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21154636.1 2021-02-01
EP21154636 2021-02-01
PCT/EP2022/052282 WO2022162233A2 (en) 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy

Publications (1)

Publication Number Publication Date
CA3206455A1 true CA3206455A1 (en) 2022-08-04

Family

ID=74494850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3206455A Pending CA3206455A1 (en) 2021-02-01 2022-02-01 Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy

Country Status (6)

Country Link
US (1) US20240116987A1 (https=)
EP (1) EP4284920A2 (https=)
JP (1) JP2024504467A (https=)
AU (1) AU2022214391A1 (https=)
CA (1) CA3206455A1 (https=)
WO (1) WO2022162233A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
US12357256B2 (en) * 2023-06-23 2025-07-15 Smart Breast Corporation Computer assisted molecular imaging methods and systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6444425B1 (en) * 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US20050130263A1 (en) * 1999-10-29 2005-06-16 Genesis Research And Development Corp. Ltd. Compositions isolated from bovine mammary gland and methods for their use
RU2556800C2 (ru) 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
CA3138822A1 (en) * 2019-05-02 2020-11-05 Universite Catholique De Louvain Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer

Also Published As

Publication number Publication date
EP4284920A2 (en) 2023-12-06
JP2024504467A (ja) 2024-01-31
WO2022162233A2 (en) 2022-08-04
WO2022162233A3 (en) 2022-11-10
AU2022214391A1 (en) 2023-08-10
US20240116987A1 (en) 2024-04-11
AU2022214391A9 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
Snyder et al. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids invivo
Nakayama et al. Fibroblast growth factor-12 (FGF12) translocation into intestinal epithelial cells is dependent on a novel cell-penetrating peptide domain: Involvement of internalization in the in vivo role of exogenous FGF12
US20170349640A1 (en) Microdystrophin peptides and methods for treating muscular dystrophy using the same
JP6249447B2 (ja) 癌治療用ペプチド剤
US11046739B2 (en) BH4 stabilized peptides and uses thereof
US20240116987A1 (en) Polypeptide inhibitors of lactate dehydrogenase activity for use in cancer therapy
IL275774A (en) Variants of ATF5 peptide and their uses
KR20200090889A (ko) Cdkl5 발현 변이체 및 cdkl5 융합 단백질
CN108884137B (zh) 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
Huang et al. Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr–Abl oncoprotein fused to the cytoplasmic transduction peptide
EP2004680B1 (en) N-terminal vdac variants and uses thereof
US20220289791A1 (en) Lactate dehydrogenase inhibitor polypeptides for use in the treatment of cancer
WO2019147979A2 (en) Peptides for angiogenic therapy
US20090137493A1 (en) Inhibition of tumor metastases using protein kinase C (PKC) inhibitors
KR20230008296A (ko) 세포 투과성 pgk1 융합단백질을 포함하는 운동신경 질환 예방 또는 치료용 약학 조성물
ES2465569T3 (es) Proteína de fusión de melusina recombinante como agente farmacológico en el tratamiento de patologías cardiacas y composiciones de la misma
Bottens et al. Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer. Cancers 2022, 14, 5546
IL194466A (en) Variants of the V-N terminal of VDAC and their use

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250117

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250127

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250127

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250127

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260108

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260108

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260108

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260120

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260218

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223